STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors and a fireside chat at the 4th Annual BTIG Ophthalmology Day.

Event: 4th Annual BTIG Ophthalmology Day Management Attendee: Thomas G. Frinzi, Chair of the Board, President and CEO Date: Monday, December 2, 2024 Fireside Chat: 4:00 p.m. ET / 1:00 p.m. PT Location: Attendance by invitation only from BTIG, the sponsoring brokerage firm.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™ product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com.

Investors & Media Brian Moore Vice President, Investor Relations and Corporate Development (626) 303-7902, Ext. 3023 bmoore@staar.com

STAAR Surgical (NASDAQ:STAA)
過去 株価チャート
から 11 2024 まで 12 2024 STAAR Surgicalのチャートをもっと見るにはこちらをクリック
STAAR Surgical (NASDAQ:STAA)
過去 株価チャート
から 12 2023 まで 12 2024 STAAR Surgicalのチャートをもっと見るにはこちらをクリック